Research programme: cardiovascular oligonucleotide therapeutics - BioMarin Pharmaceutical
Latest Information Update: 23 Apr 2024
At a glance
- Originator BioMarin Pharmaceutical
- Class Cardiovascular therapies; Oligonucleotides
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders
Most Recent Events
- 23 Apr 2024 Preclinical trials in Cardiovascular disorders in USA (Parenteral) before April 2024 (BioMarin Pharmaceutical pipeline, April 2024)
- 22 Sep 2023 Early research in Cardiovascular disorders in USA (Parenteral) (BioMarin Pharmaceutical pipeline, September 2023)